Multidisciplinary clinical management of paroxysmal nocturnal hemoglobinuria.
- 15 June 2015
- journal article
- review article
- Vol. 5 (1) , 1-9
Abstract
Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, acquired disease caused by clonal expansion of one or more hematopoietic stem cell (HSC) lines due to a somatic mutation of the phosphatidylinositol glycan anchor (PIG-A) gene located on Xp22.1. PNH incidence is 1.5-2 cases per million of the population per year. PNH can affect multiple systems in the body and requires multidisciplinary clinical management. Patients can manifest with severe pancytopenia, life-threatening thrombosis affecting the hepatic, abdominal, cerebral, and subdermal veins, and high requirements for blood transfusion due to haemolytic anemia. PNH can also be associated with bone marrow failure. Advances in diagnostic techniques and a targeted therapeutic approach for PNH have emerged in the last two decades. Eculizumab, a promising humanized monoclonal antibody against C5, is the first approved therapy for PNH.Keywords
This publication has 31 references indexed in Scilit:
- Paroxysmal nocturnal hemoglobinuria (PNH): higher sensitivity and validity in diagnosis and serial monitoring by flow cytometric analysis of reticulocytesAnnals of Hematology, 2011
- Paroxysmal nocturnal hemoglobinuria: natural history of disease subcategoriesBlood, 2008
- Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuriaBlood, 2008
- Monocyte-derived microparticles and exosomes induce procoagulant and apoptotic effects on endothelial cellsThrombosis and Haemostasis, 2008
- Clinical Course and Flow Cytometric Analysis of Paroxysmal Nocturnal Hemoglobinuria in the United States and JapanMedicine, 2004
- Resistance to apoptosis caused byPIG-Agene mutations in paroxysmal nocturnal hemoglobinuriaProceedings of the National Academy of Sciences, 1997
- Inhibition of complement activity by humanized anti-C5 antibody and single-chain FvMolecular Immunology, 1996
- Paroxysmal nocturnal haemoglobinuria: long-term follow-up and prognostic factorsThe Lancet, 1996
- Natural History of Paroxysmal Nocturnal HemoglobinuriaNew England Journal of Medicine, 1995
- Molecular basis of the enhanced susceptibility of the erythrocytes of paroxysmal nocturnal hemoglobinuria to hemolysis in acidified serum.1991